TY - JOUR T1 - Scalable, effective, and rapid decontamination of SARS-CoV-2 contaminated N95 respirators using germicidal ultra-violet C (UVC) irradiation device JF - medRxiv DO - 10.1101/2020.10.05.20206953 SP - 2020.10.05.20206953 AU - Raveen Rathnasinghe AU - Robert F. Karlicek, Jr. AU - Michael Schotsaert AU - Mattheos Koffas AU - Brigitte Arduini AU - Sonia Jangra AU - Bowen Wang AU - Jason L. Davis AU - Mohammed Alnaggar AU - Anthony Costa AU - Richard Vincent AU - Adolfo Garcia-Sastre AU - Deepak Vashishth AU - Priti Balchandani Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/06/2020.10.05.20206953.abstract N2 - Importance Particulate respirators such as N95 masks are an essential component of personal protective equipment (PPE) for front-line workers. This study describes a rapid and effective UVC irradiation system that would facilitate the safe re-use of N95 respirators and provides supporting information for deploying UVC for decontamination of SARS-CoV-2 during the COVID19 pandemic.Objective To assess the inactivation potential of the proposed UVC germicidal device as a function of time by using 3M® 8211 - N95 particulate respirators inoculated with SARS-CoV-2.Design A germicidal UVC device to deliver tailored UVC dose was developed and snippets (2.5cm2) of the 3M-N95 respirator were inoculated with 106 plaque-forming units (PFU) of SARS-CoV-2 and were UV irradiated. Different exposure times were tested (0-164 seconds) by fixing the distance between the lamp (10 cm) and the mask while providing an exposure of at least 5.43 mWcm-2.Setting The current work is broadly applicable for healthcare-settings, particularly during a pandemic such as COVID-19.Participants Not applicable.Main Outcome(s) and Measure(s) Primary measure of outcome was titration of infectious virus recovered from virus-inoculated respirator pieces after UVC exposure. Other measures included the method validation of the irradiation protocol, using lentiviruses (biosafety level-2 agent) and establishment of the germicidal UVC exposure protocol.Results An average of 4.38×103 PFUml-1(SD 772.68) was recovered from untreated masks while 4.44×102 PFUml-1(SD 203.67), 4.00×102 PFUml-1(SD 115.47), 1.56×102 PFUml-1(SD 76.98) and 4.44×101 PFUml-1(SD 76.98) was recovered in exposures 2s,6s,18s and 54 seconds per side respectively. The germicidal device output and positioning was monitored and a minimum output of 5.43 mWcm-2 was maintained. Infectious SARS-CoV-2 was not detected by plaque assays (minimal level of detection is 67 PFUml-1) on N95 respirator snippets when irradiated for 120s per side or longer suggesting 3.5 log reduction in 240 seconds of irradiation.Conclusions and Relevance A scalable germicidal UVC device to deliver tailored UVC dose for rapid decontamination of SARS-CoV-2 was developed. UVC germicidal irradiation of N95 snippets inoculated with SARS-CoV-2 for 120s per side resulted in 100% (3.5 log in total) reduction of virus. These data support the reuse of N95 particle-filtrate apparatus upon irradiation with UVC and supports use of UVC-based decontamination of SARS-CoV-2 virus during the COVID19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was partly funded by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C); by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)), anonymous donors to AG-S, funds from Rensselaer Polytechnic Institute and NIH (5UL1TR001433).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The reported finding did not involve research on human subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available through email request to the corresponding author, Dr. Priti Balchandani. ER -